Pharmacokinetic characterization of the novel TAZ modulator TM-25659 using a multicompartment kinetic model in rats and a possibility of its drug–drug interactions in humans

References

• Beubler E, Lembeck F. (1979). Inhibition of stimulated fluid secretion in the rat small and large intestine by opiate agonists. Naunyn Schmiedebergs Arch Pharmacol 306:113–118.
   PubMedGoogle Scholar
• Chan SW, Lim CJ, Guo K, Ng CP, Lee I, Hunziker W, Zeng Q, Hong W. (2008). A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res 68:2592–2598.
   PubMed Web of Science ®Google Scholar
• Choi SH, Lee KR, Woo JC, Kim NJ, Moon DC, Hwang ES, Ahn SH, Bae MA, Kim MS. (2012). Determination of a novel TAZ modulator, 2-butyl-5-methyl-6-(pyridine-3-yl)-3-[2′-(1H-tetrazole-5-yl)-biphenyl-4-ylmethyl]-3H imidazo[4,5-b]pyridine] (TM-25659) in rat plasma by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 63:47–52.
   PubMedGoogle Scholar
• Cui CB, Cooper LF, Yang X, Karsenty G, Aukhil I. (2003). Transcriptional coactivation of bone-specific transcription factor Cbfa1 by TAZ. Mol Cell Biol 23:1004–1013.
   PubMedGoogle Scholar
• FDA US. (2001). Guidance for industry: bioanalytical method validation. Rockville, MD: CDER.
   Google Scholar
• Fu H, Subramanian RR, Masters SC. (2000). 14-3-3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol 40:617–647.
   PubMed Web of Science ®Google Scholar
• Harada S, Rodan GA. (2003). Control of osteoblast function and regulation of bone mass. Nature 423:349–355.
   PubMed Web of Science ®Google Scholar
• Hong JH, Hwang ES, McManus MT, Amsterdam A, Tian Y, Kalmukova R, Mueller E, Benjamin T, Spiegelman BM, Sharp PA, Hopkins N, Yaffe MB. (2005). TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 309:1074–1078.
   PubMed Web of Science ®Google Scholar
• Hong JH, Yaffe MB. (2006). TAZ: a beta-catenin-like molecule that regulates mesenchymal stem cell differentiation. Cell Cycle 5:176–179.
   PubMed Web of Science ®Google Scholar
• Jang EJ, Jeong H, Kang JO, Kim NJ, Kim MS, Choi SH, Yoo SE, Hong JH, Bae MA, Hwang ES. (2012). TM-25659 enhances osteogenic differentiation and suppresses adipogenic differentiation by modulating the transcriptional co-activator TAZ. Br J Pharmacol 165:1584–1594.
   PubMedGoogle Scholar
• Kanai F, Marignani PA, Sarbassova D, Yagi R, Hall RA, Donowitz M, Hisaminato A, Fujiwara T, Ito Y, Cantley LC, Yaffe MB. (2000). TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J 19:6778–6791.
   PubMed Web of Science ®Google Scholar
• Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S, Kishimoto T. (1997). Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89:755–764.
   PubMed Web of Science ®Google Scholar
• Lee KR, Chae YJ, Maeng HJ, Lee J, Kim DD, Chong S, Shim CK, Chung SJ. (2011). Physiologically based pharmacokinetic modeling of SNU-0039, an anti-Alzheimer’s agent, in rats. J Pharmacokinet Pharmacodyn 38:637–651.
   PubMedGoogle Scholar
• Mahoney WM Jr, Hong JH, Yaffe MB, Farrance IK. (2005). The transcriptional co-activator TAZ interacts differentially with transcriptional enhancer factor-1 (TEF-1) family members. Biochem J 388:217–225.
   PubMedGoogle Scholar
• Murakami M, Nakagawa M, Olson EN, Nakagawa O. (2005). A WW domain protein TAZ is a critical coactivator for TBX5, a transcription factor implicated in Holt-Oram syndrome. Proc Natl Acad Sci USA 102:18034–18039.
   PubMedGoogle Scholar
• Murakami M, Tominaga J, Makita R, Uchijima Y, Kurihara Y, Nakagawa O, Asano T, Kurihara H. (2006). Transcriptional activity of Pax3 is co-activated by TAZ. Biochem Biophys Res Commun 339:533–539.
   PubMed Web of Science ®Google Scholar
• Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, Stamp GW, Beddington RS, Mundlos S, Olsen BR, Selby PB, Owen MJ. (1997). Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89:765–771.
   PubMed Web of Science ®Google Scholar
• Park KS, Whitsett JA, Di Palma T, Hong JH, Yaffe MB, Zannini M. (2004). TAZ interacts with TTF-1 and regulates expression of surfactant protein-C. J Biol Chem 279:17384–17390.
   PubMedGoogle Scholar
• Song JS, Chae JW, Lee KR, Lee BH, Choi EJ, Ahn SH, Kwon KI, Bae MA. (2011). Pharmacokinetic characterization of decursinol derived from Angelica gigas Nakai in rats. Xenobiotica 41:895–902.
   PubMed Web of Science ®Google Scholar
• Tian Y, Li D, Dahl J, You J, Benjamin T. (2004). Identification of TAZ as a binding partner of the polyomavirus T antigens. J Virol 78:12657–12664.
   PubMedGoogle Scholar